Especially, the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody bevacizumab has become the standard of care as a first-line therapy for HCC (Sangro et al., 2021). This evidence concerns the gene CD274 and hepatocellular carcinoma.